𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Dysregulation and overexpression of HMGA2 in myelofibrosis with myeloid metaplasia

✍ Scribed by Joris Andrieux; Jean-Loup Demory; Brigitte Dupriez; Sabine Quief; Isabelle Plantier; Christophe Roumier; Francis Bauters; Jean Luc Laï; Jean-Pierre Kerckaert


Publisher
John Wiley and Sons
Year
2003
Tongue
English
Weight
262 KB
Volume
39
Category
Article
ISSN
1045-2257

No coin nor oath required. For personal study only.

✦ Synopsis


Among cytogenetic studies of patients affected with myelofibrosis with myeloid metaplasia (MMM), a rare chronic myeloproliferative disorder, we found several reports of structural abnormalities of the long arm of chromosome 12. Two MMM patients had a balanced translocation involving 12q: t(4;12)(q32;q15) and t(5;12)(p14;q15), respectively. FISH (fluorescence in situ hybridization) analysis showed that BAC (bacterial artificial chromosome) RP11-366L20 overlaps the breakpoint in both cases. A gene, HMGA2, most of which is included in that BAC, thus was identified as a potential candidate. Using reserves transcriptase-polymerase chain reaction (RT-PCR), we looked for expression of HMGA2 in blood mononuclear cells from these 2 patients and demonstrated a transcript in both. Moreover, we found the gene expressed in the hematopoietic cells of 10 of 10 additional patients bearing no 12q anomalies. HMGA2, not expressed in normal subjects, is implicated in benign solid tumors such as lipomas, leiomyomas, and other rare tumors of mesenchymal origin. We postulate that its dysregulation and overexpression in myeloid progenitors contribute also to the pathogenesis of MMM.


📜 SIMILAR VOLUMES


Prognostic diversity among cytogenetic a
✍ Ayalew Tefferi; David Dingli; Chin-Yang Li; Gordon W. Dewald 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 88 KB

## Abstract ## BACKGROUND Approximately 30–50% of patients with myelofibrosis with myeloid metaplasia (MMM) demonstrate detectable cytogenetic abnormalities, the prognostic value of which has not been completely defined by previous retrospective studies. The current prospective study addresses thi

Leukemogenic risk of hydroxyurea therapy
✍ Nand, Sucha; Stock, Wendy; Godwin, John; Fisher, Susan Gross 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 417 KB 👁 2 views

In polycythemia Vera (PV), treatment with chlorambucil and radioactive phosphorus (p32) increases the risk of leukemic transformation from 1% to 13-14%. This risk has been estimated to be 1-5.9% with hydroxyurea (HU) therapy. When compared with historical controls, the risk with use of HU does not a

Dyspnea secondary to pulmonary hematopoi
✍ Elisa Rumi; Francesco Passamonti; Emanuela Boveri; Mara De Amici; Cesare Astori; 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 272 KB

We report a case of a patient with myelofibrosis with myeloid metaplasia (MMM) who presented with progressive dyspnea of unexplained origin. Splenomegaly, blood smear, and bone marrow findings allowed diagnosis of MMM. High-resolution CT chest scan revealed diffuse septal thickening, while echocardi